Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Natalizumab

Nature Reviews Drug Discovery volume 4, pages 101–102 (2005)Cite this article

Abstract

Natalizumab (Tysabri; Biogen Idec/Elan) is a humanized antibody against the α4 integrin subunit, which is involved in the migration of immune system cells into the central nervous system. It was approved by the US FDA for the treatment of multiple sclerosis in November 2004.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Simplified view of selected steps in the pathogenesis of MS.

References

  1. Noseworthy, J. H. et al. Multiple sclerosis. N. Engl. J. Med. 343, 938–952 (2000).

    CAS  Google Scholar 

  2. Polman, C. H. & Uitdehaag, B. M. J. New and emerging treatment options for multiple sclerosis. Lancet Neurol. 2, 563–566 (2003).

    Article  CAS  Google Scholar 

  3. Yednock, T. A. et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 356, 63–66 (1992).

    Article  CAS  Google Scholar 

  4. Engelhardt, B. et al. The development of experimental autoimmune encephalomyelitis in the mouse requires α4-integrin but not α4β7-integrin. J. Clin. Invest. 102, 2096–2105 (1998).

    Article  CAS  Google Scholar 

  5. Leger, O. J. et al. Humanization of a mouse antibody against human α-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum. Antibodies 8, 3–16 (1997).

    Article  CAS  Google Scholar 

  6. Miller, D. H. et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15–23 (2003).

    Article  CAS  Google Scholar 

  7. FDA labelling information [online], <http://www.fda.gov/cder/foi/label/2004/125104lbl.pdf> (2004).

  8. Cohen, J. A. & Antel, J. P. Does interferon-β help in secondary progressive MS? Neurology 63, 1768–1769 (2004).

    Article  Google Scholar 

  9. Lucchinetti, C. et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47, 707–717 (2000).

    Article  CAS  Google Scholar 

  10. Steinman, L. & Zamvil, S. et al. Transcriptional analysis of targets in multiple sclerosis. Nature Rev. Immunol. 3, 483–492 (2003).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, 55905, Minnesota, USA

    John H. Noseworthy

  2. Nature Reviews Drug Discovery,

    Peter Kirkpatrick

Authors
  1. John H. Noseworthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to John H. Noseworthy or Peter Kirkpatrick.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Noseworthy, J., Kirkpatrick, P. Natalizumab. Nat Rev Drug Discov 4, 101–102 (2005). https://doi.org/10.1038/nrd1637

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1637

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing